Annual report pursuant to Section 13 and 15(d)

Reverse Acquisition (Details Narrative)

v3.8.0.1
Reverse Acquisition (Details Narrative) - USD ($)
 12 Months Ended
Oct. 04, 2017
Sep. 29, 2017
Dec. 31, 2017
Dec. 31, 2016
Common stock shares issued     35,272,626 31,745,242
Common stock shares outstanding     35,272,626 31,745,242
Promet Therapeutics LLC [Member]        
General and administrative expense     $ 58,763  
Parent Company [Member]        
Business acquisition acquired value $ 1,017,342      
Business acquisition exchange percentage 90.00%      
Business acquisition of common stock issued shares 222,217,112      
Stock issued during reserve split 31,745,242 1,850,625 35,272,626  
Common stock shares issued     246,907,902  
Common stock shares outstanding     246,907,902